Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Pharmacokinetics and Point of Care Testing After a Single Dose of 150 mg Dabigatran, 20 mg Rivaroxaban, 5 mg Apixaban, and 60 mg Edoxaban in Healthy Male Subjects

NCT05491460 is registered in ClinicalTrials.gov with Doasense GmbH as lead sponsor.

NCT NCT05491460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05491460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Pharmacokinetics and Point of Care Testing After a Single Dose of 150 mg Dabigatran, 20 mg Rivaroxaban, 5 mg Apixaban, and 60 mg Edoxaban in Healthy Male Subjects
Lead sponsor
Doasense GmbH
Phase
Phase 1
Overall status
Unknown status
Start date
July 1, 2022
Completion date
December 30, 2023
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulant therapy